Clinical and in vitro data indicate that MAOA functions as a tumor suppressor in hepatocellular carcinoma (11), cholangiocarcinoma (12), pheochromocytoma (13), neuroblastoma (14), renal cell carcinoma (15), and oral and pharyngeal cancers (16). This evidence concerns the gene MAOA and neoplasm.